Formulated with B12 and glycine to reduce nausea and protect muscles
Acta Clin Belg 63(6):402407 Scheen AJ (2021) Efficacy/safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
Lee WC, Gomez DR, Ahang J, Jalali A, Roh W, Reuben A, Lu W, Chow CW, Wu CC, Fujimoto J, Antonoff M, Moran C, Sulman EP, Rao G, Swisher SG , Heymach J, Wistuba II, Futreal A, Zhang J
Kidney disease in patients with gout is of numerous types
A trial of omarigliptin evaluated 4202 diabetic patients without acute ischemic disease, who were followed for a median of 1.8 years, before early termination of the trial [50]
While injectable formulations remain effective, their limitations in patient adherence have driven innovation toward more convenient and patient-friendly delivery systems